- Home
- REI vs MIST Comparison
REI vs MIST Comparison
Compare REI & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | REI | MIST |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 181.3M | 176.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | REI | MIST |
|---|---|---|
| Price | $0.99 | $2.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 1.5M | ★ 3.9M |
| Earning Date | 03-04-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $308,790,652.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.43 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.72 | $0.63 |
| 52 Week High | $1.51 | $3.06 |
Technical Indicators
Market Signals| Indicator | REI | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 64.94 | 43.70 |
| Support Level | $0.93 | $1.97 |
| Resistance Level | $1.01 | $2.13 |
| Average True Range (ATR) | 0.05 | 0.12 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 87.79 | 31.25 |
Price Performance
Historical ComparisonAbout REI Ring Energy Inc.
Ring Energy Inc is an independent exploration and production company based in The Woodlands, Texas and is engaged in oil and natural gas development, production, acquisition, and exploration activities currently focused in the Permian Basin of Texas. The drilling operations of the company target the oil and liquid rich producing formations in the Northwest Shelf, the Central Basin Platform and the Delaware Basin all of which are part of the Permian Basin in Texas.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).